żDeben los nińos tomar antidepresivos?

Durante los pasados 12 meses he sido testigo de cambios radicales y un alto nivel de controversia acerca del modo como se trata la depresión infantil y adolescente. Aunque pocos antidepresivos han sido autorizados para uso pediátrico, los índices de prescripción en el grupo de menores de 18 ańos han aumentado en cerca de un 60% en la última década: más de un millón de nińos y adolescentes reciben los llamados inhibidores selectivos de la recaptación de la serotonina (ISRS).

Sin embargo, en la actualidad la preocupación acerca de la seguridad y los efectos secundarios de tales medicamentos en este grupo (lo que incluye elevados índices de suicidio) ha despertado a los entes reguladores de varios países. Tras evaluar todos los ensayos pediátricos pertinentes, la Agencia Reguladora de Medicamentos y Productos para el Cuidado de la Salud (MHRA) del Reino Unido indicó que los riesgos superan a los beneficios en el caso de la casi totalidad de los ISRS, con excepción de la fluoxetina, y que estos productos no se deben recetar como una nueva terapia para pacientes menores de 18 ańos con enfermedades depresivas.

Por vez primera, la MHRA hizo público un resumen de la evaluación en que basó esta decisión, lo que incluye información sobre la eficacia y seguridad de todos los ensayos, independientemente de si había sido publicada previamente o no. Esto ha sido importante, ya que la mitad de los ensayos no habían sido publicados en revistas periódicas especializadas.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.

required

Log in

http://prosyn.org/89OHjFA/es;
  1. Chris J Ratcliffe/Getty Images

    The Brexit Surrender

    European Union leaders meeting in Brussels have given the go-ahead to talks with Britain on post-Brexit trade relations. But, as European Council President Donald Tusk has said, the most difficult challenge – forging a workable deal that secures broad political support on both sides – still lies ahead.

  2. The Great US Tax Debate

    ROBERT J. BARRO vs. JASON FURMAN & LAWRENCE H. SUMMERS on the impact of the GOP tax  overhaul.


    • Congressional Republicans are finalizing a tax-reform package that will reshape the business environment by lowering the corporate-tax rate and overhauling deductions. 

    • But will the plan's far-reaching changes provide the boost to investment and growth that its backers promise?


    ROBERT J. BARRO | How US Corporate Tax Reform Will Boost Growth

    JASON FURMAN & LAWRENCE H. SUMMERS | Robert Barro's Tax Reform Advocacy: A Response

  3. Murdoch's Last Stand?

    Rupert Murdoch’s sale of 21st Century Fox’s entertainment assets to Disney for $66 billion may mark the end of the media mogul’s career, which will long be remembered for its corrosive effect on democratic discourse on both sides of the Atlantic. 

    From enabling the rise of Donald Trump to hacking the telephone of a murdered British schoolgirl, Murdoch’s media empire has staked its success on stoking populist rage.

  4. Bank of England Leon Neal/Getty Images

    The Dangerous Delusion of Price Stability

    Since the hyperinflation of the 1970s, which central banks were right to combat by whatever means necessary, maintaining positive but low inflation has become a monetary-policy obsession. But, because the world economy has changed dramatically since then, central bankers have started to miss the monetary-policy forest for the trees.

  5. Harvard’s Jeffrey Frankel Measures the GOP’s Tax Plan

    Jeffrey Frankel, a professor at Harvard University’s Kennedy School of Government and a former member of President Bill Clinton’s Council of Economic Advisers, outlines the five criteria he uses to judge the efficacy of tax reform efforts. And in his view, the US Republicans’ most recent offering fails miserably.

  6. A box containing viles of human embryonic Stem Cell cultures Sandy Huffaker/Getty Images

    The Holy Grail of Genetic Engineering

    CRISPR-Cas – a gene-editing technique that is far more precise and efficient than any that has come before it – is poised to change the world. But ensuring that those changes are positive – helping to fight tumors and mosquito-borne illnesses, for example – will require scientists to apply the utmost caution.

  7. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now